News headlines about Peregrine Pharmaceuticals (NASDAQ:PPHM) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Peregrine Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 48.0688449932088 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have effected Accern’s analysis:
- Peregrine Pharmaceuticals Inc. (PPHM) Raised to Hold at Zacks Investment Research (americanbankingnews.com)
- Head to Head Review: Peregrine Pharmaceuticals (PPHM) versus Its Peers (americanbankingnews.com)
- Universal Health Services, Inc. (UHS) and Peregrine Pharmaceuticals, Inc. (PPHM) closes with a move of 1.66% – Stocks Gallery (stocksgallery.com)
- Peregrine’s Well Is Running Dry – Seeking Alpha (seekingalpha.com)
- ETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 14, 2017 (finance.yahoo.com)
Peregrine Pharmaceuticals (NASDAQ PPHM) remained flat at $3.12 during mid-day trading on Tuesday. The company had a trading volume of 19,175 shares. Peregrine Pharmaceuticals has a 52-week low of $1.97 and a 52-week high of $5.78. The stock’s market cap is $139.69 million. The company’s 50-day moving average is $3.39 and its 200-day moving average is $4.12.
Peregrine Pharmaceuticals (NASDAQ:PPHM) last announced its quarterly earnings results on Monday, September 11th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06. Peregrine Pharmaceuticals had a negative return on equity of 38.19% and a negative net margin of 23.15%. The company had revenue of $27.08 million during the quarter, compared to analyst estimates of $15.22 million. On average, analysts anticipate that Peregrine Pharmaceuticals will post ($0.40) EPS for the current year.
PPHM has been the subject of a number of recent research reports. ValuEngine downgraded Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 9th. BidaskClub upgraded Peregrine Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, July 17th. Zacks Investment Research downgraded Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 21st. Finally, Noble Financial restated a “buy” rating on shares of Peregrine Pharmaceuticals in a research report on Monday, July 31st.
COPYRIGHT VIOLATION NOTICE: “Peregrine Pharmaceuticals (PPHM) Earns Daily News Sentiment Score of 0.16” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/09/19/peregrine-pharmaceuticals-pphm-earns-daily-news-sentiment-score-of-0-16.html.
Peregrine Pharmaceuticals Company Profile
Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.
Receive News & Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.